Literature DB >> 1237820

Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man.

J P Morgan, L Rivera-Calimlim, F Messiha, P R Sundaresan, N Trabert.   

Abstract

The effect of imipramine on the absorption of a single dose of levodopa was studied in male volunteers. By delaying gastric emptying and retarding delivery to intestinal absorptive sites, imipramine interfered with the absorption of levodopa. This action caused by the anticholinergic effect of imipramine. The retardation of transit of levodopa also caused the elaboration of therapeutically inactive metabolites of levodopa in the gastrointestinal tract. Antidepressants and levodopa are often given together, and this combination may interfere with the absorption and efficacy of levodopa in the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1237820     DOI: 10.1212/wnl.25.11.1029

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

Review 3.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 4.  Antiparkinsonian agents. Drug interactions of clinical significance.

Authors:  R F Pfeiffer
Journal:  Drug Saf       Date:  1996-05       Impact factor: 5.606

5.  Antiparkinsonian Agents : Clinically Significant Drug Interactions and Adverse Effects, and Their Management.

Authors:  A Dalvi; B Ford
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 6.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

7.  Domperidone and levodopa in Parkinson's disease.

Authors:  J S Shindler; G T Finnerty; K Towlson; A L Dolan; C L Davies; J D Parkes
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

Review 8.  Pharmacokinetics of drug overdose.

Authors:  J Rosenberg; N L Benowitz; S Pond
Journal:  Clin Pharmacokinet       Date:  1981 May-Jun       Impact factor: 6.447

Review 9.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.